Galmed announces first time results in oncology studies: aramchol significantly enhances bayer's regorafenib effect in gi cancer models

Results from studies at virginia commonwealth university (vcu) show that an aramchol and bayer's regorafenib drug combination significantly reduced hepatic tumor growth in mice models. the cell killing effect in-vitro and in-vivo was due to increased autophagy and death receptor signaling.
GLMD Ratings Summary
GLMD Quant Ranking